Can Sildenafil Citrate Be a Game Changer in the Management of Tuberculosis? A Food for Thought?
Abstract
Isoniazid (INH) and Rifampicin (RIF) are cornerstone drugs in tuberculosis therapy but are known to cause hepatotoxicity. Sildenafil citrate, a phosphodiesterase-5 inhibitor, has shown potential antioxidant and anti-inflammatory properties, yet its hepatoprotective effects have not been extensively evaluated. Objective: To investigate the biochemical changes induced by combined INH-RIF therapy and assess the potential hepatoprotective effects of sildenafil treatment in a murine model. Methods: This randomized experimental study involved 21 Swiss albino mice (25–35 g), divided into three groups (n=7 each) using simple balloting. Group C (control) received 0.4 mL/kg normal saline intraperitoneally for 21 days. Group R (INH-RIF) was administered isoniazid and rifampicin (50 mg/kg each) intraperitoneally, daily for 21 days. Group S (INH-RIF + Sildenafil) received the same INH-RIF regimen with concurrent oral sildenafil (10 mg/kg) via gastric gavage. At the end of treatment, serum liver function tests (LFTs) were analyzed. Data were processed using descriptive statistics; inter-group differences were assessed using appropriate statistical tests with significance set at p < 0.05. Results: Group R exhibited significant elevation in serum hepatic enzymes indicating hepatotoxicity. Group S showed marked improvement in LFT parameters compared to Group R, suggesting attenuation of hepatotoxicity. Group C maintained normal hepatic profiles. Sildenafil administration resulted in a…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.